DDInter556 DDInter1825
Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis. It was marketed in 1911.
Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer.
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Nalbuphine
Nalbuphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Galantamine
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Nalbuphine
Nalbuphine {u} may lead to a major life threatening interaction when taken with {v} Opium
Opium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Morphine
Morphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Fostamatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Oxymorphone
Oxymorphone {u} (Compound) resembles {v} (Compound) Nalbuphine
Nalbuphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Galantamine
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Fostamatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Hydromorphone
Hydromorphone {u} (Compound) resembles {v} (Compound) Nalbuphine
Nalbuphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Nalbuphine
Nalbuphine {u} may lead to a major life threatening interaction when taken with {v} Morphine
Morphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Nalbuphine
Nalbuphine {u} (Compound) resembles {v} (Compound) Oxycodone
Oxycodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Morphine
Morphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clonidine
Clonidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Dihydrocodeine (Compound) resembles Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Dihydrocodeine (Compound) resembles Galantamine (Compound) and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Dihydrocodeine (Compound) resembles Nalbuphine (Compound) and Nalbuphine may lead to a major life threatening interaction when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Dihydrocodeine (Compound) resembles Morphine (Compound) and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Dihydrocodeine (Compound) resembles Oxymorphone (Compound) and Oxymorphone (Compound) resembles Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Dihydrocodeine (Compound) resembles Galantamine (Compound) and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Dihydrocodeine (Compound) resembles Hydromorphone (Compound) and Hydromorphone (Compound) resembles Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Dihydrocodeine (Compound) resembles Nalbuphine (Compound) and Nalbuphine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Dihydrocodeine (Compound) resembles Nalbuphine (Compound) and Nalbuphine (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Dihydrocodeine (Compound) resembles Morphine (Compound) and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib